ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1655

Lupus Nephritis: Clinicopathological Correlation in 126 Biopsies

Milagros Ricse1, Javier Narváez2, Gloria Albert1, Paula Estrada1, Helena Borrell1, Eugenia de Lama3, Xavier Fulladosa4, Manel Rubio Rivas5, Olga Capdevila5, Francesca Mitjavila5, Xavier Juanola6 and Joan Miquel Nolla1, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, 3Radiology, Hospital Universitario de Bellvitge, Barcelona, Spain, 4Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain, 5Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, 6Rheumatology, University Hospital Bellvitge, Barcelona, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: biopsies, Nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: To analyze the correlation between clinical and laboratory data and type of histological injury in a cohort of patients with lupus nephritis (LN).

Methods: The sample comprised 243 patients with SLE treated between 1980 and 2013 at a tertiary university hospital that does not attend pediatric populations. Patients were registered in a specific database. Patients diagnosed with LN classes 2-5 according to the WHO classification or the ISN/RPS classification (in use since 2004) were selected for analysis. In each case, the presence of arterial hypertension, renal insufficiency (RI), nephrotic syndrome (NS), hematuria, and cylindruria was assessed at the time of the biopsy; 24-h urine protein value was also recorded.

The specificity, sensitivity, PPV, NPV, LR +,  LR-, and accuracy  for each of the clinical and laboratory data in order to diagnose the different histological types of LN.

Results: The diagnoses were: a) Class II Mesangial proliferative lupus nephritis, 45 cases (35%); b) Class III Focal lupus nephritis, 16 (13%); c) Class IV Diffuse lupus nephritis 49 (39%), and d) Class V Membranous lupus nephritis,16 (13%).

The mean levels of proteinuria were: a) class II; 1.62 g/24 h; b) class III: 1.53 g/24 h; c) class IV; 2.12 g/24 d) class V; 5.15 g/24 h. The only significant differences observed were between LN class V and the other histological types of LN. Five patients had proteinuria below 0.5 g/24 h (3 class II and 2 class IV) and 12 had proteinuria 0.5-1 g/24 (3 class II, 3 III, 4 IV and 2 class V).

The discriminative values of other clinical and laboratory data for the diagnosis of the different types of LN are shown in Table 1.

 

 

Sensitivity

Specificity

PPV

NPV

LR+

LR-

Accuracy

CLASS II

Renal insufficiency

Arterial Hypertension

Nephrotic syndrome

Hematuria

Cylindruria

–

4%

4%

18%

69%

4%

–

83%

78%

54%

40%

81%

–

13%

10%

18%

39%

12%

–

61%

59%

54%

70%

61%

–

0.26

0.20

0.39

1.14

0.24

 

–

1.16

1.23

1.51

0.79

1.17

–

0.547

0.515

0.412

0.500

0.539

CLASS III

Renal insufficiency

Arterial Hypertension

Nephrotic syndrome

Hematuria

Cylindruria

–

6%

6%

6%

56%

13%

 

–

86%

83%

60%

35%

87%

–

6%

5%

2%

11%

13%

–

86%

86%

81%

85%

87%

–

0.46

0.36

0.16

0.87

0.98

–

1.09

1.13

1.56

1.23

1.00

–

0.761

0.730

0.531

0.380

0.777

CLASS IV

Renal insufficiency

Arterial Hypertension

Nephrotic syndrome

Hematuria

Cylindruria

–

20%

35%

53%

61%

22%

 

–

94%

96%

75%

35%

94%

–

67%

85%

58%

38%

69%

–

65%

70%

72%

59%

65%

–

3.14

8.90

2.15

0.94

3.46

 

–

0.85

0.68

0.62

1.11

0.83

 

–

0.650

0.722

0.666

0.452

0.658

CLASS  V

Renal insufficiency

Arterial Hypertension

Nephrotic syndrome

Hematuria

Cylindruria

–

19%

0%

63%

63%

13%

–

88%

82%

68%

36%

87%

 

–

19%

0%

22%

13%

13%

–

88%

85%

93%

87%

87%

–

1.59

0.00

1.96

0.98

0.98

 

–

0.92

1.22

0.55

1.03

1.00

–

0.793

0.714

0.674

0.396

0.777

Parameters with a high LR + (greater than 3) and an acceptable diagnostic accuracy were the presence of RI, arterial hypertension and cylindruria in LN class IV. The presence of NS in classes IV and V also had a relatively high LR +. However, at the time of diagnosis or during follow-up, eight patients with LN class II had NS (excluding those patients with nephrotic-range proteinuria undergoing class transformation). Although uncommon, the presence of cylindruria was also observed in LN class II (one patient), class III (2) and type V (2) .

In LN class II, none of the clinical and laboratory data had a LR- high enough (<0.5 to 0.3) to be a useful parameter to discard it.

Conclusion: In LN, only class IV and to a lesser extent class V present a good correlation between the clinical/ laboratory and histological data. In general, clinical/laboratory data cannot predict the type of histological lesion. In our experience, more than half of patients with mild proteinuria (below 1 g/24 h) presented advanced forms of LN (classes III, IV or V).


Disclosure:

M. Ricse,
None;

J. Narváez,
None;

G. Albert,
None;

P. Estrada,
None;

H. Borrell,
None;

E. de Lama,
None;

X. Fulladosa,
None;

M. Rubio Rivas,
None;

O. Capdevila,
None;

F. Mitjavila,
None;

X. Juanola,
None;

J. M. Nolla,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-nephritis-clinicopathological-correlation-in-126-biopsies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology